Serum carbamazepine concentrations in elderly patients: A case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data

Epilepsia

Volumn 44, Issue 7, 2003, Pages 923-929

  Battino, Dina ^a   Croci, Danilo ^a   Rossini, Alessandro ^a   Messina, Sara ^b   Mamoli, Daniela ^a   Perucca, Emilio ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Carbamazepine; Drug therapy; Elderly; Epilepsy; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

CARBAMAZEPINE; PHENOBARBITAL;

AGED; AGING; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CALCULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DRUG MONITORING; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METABOLIC RATE; MULTIPLE REGRESSION; PRIORITY JOURNAL; REDUCTION; RETROSPECTIVE STUDY; STEADY STATE;

ADULT; AGE FACTORS; AGED; ANTICONVULSANTS; CARBAMAZEPINE; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHENOBARBITAL; REFERENCE VALUES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 0038153195     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2003.62202.x     Document Type: Article

References (33)

1. Beghi E, Perucca E. The management of epilepsy in the 1990s: acquisitions, uncertainties and priorities for future research. Drugs 1995;49:680-94.
2. Beghi E. Carbamazepine: clinical efficacy and use in other neurological disorders, In: Levy R, Mattson R, Meldrum B, et al., eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:273-7.
3. Trimble MR. Carbamazepine: clinical efficacy and use in psychiatric disorders. In: Levy R, Mattson R, Meldrum B, et al., eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:278-84.
4. Tallis R, Hall G, Craig I, et al. How common are epileptic seizures in old age? Age Ageing 1991;20:442-8.
5. Willmore LJ. The effect of age on pharmacokinetics of antiepileptic drugs. Epilepsia 1995;36:S14-21.
6. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 1999;37:81-7.
7. Stephens LJ, Brodie MJ. Epilepsy in elderly people. Lancet 2000;355:1441-6.
8. Willmore LJ. Choice and use of newer anticonvulsant drugs in older patients. Drugs Aging 2000;17:441-52.
9. Cloyd JC, Lackner TE, Leppik IE. Antiepileptics in the elderly: pharmacoepidemiology and pharmacokinetics. Arch Fam Med 1994;3:589-98.
10. Schachter SC, Cramer GW, Thompson GD, et al. An evaluation of antiepileptic drug therapy in nursing facilities. J Am Geriatr Soc 1998;46:1137-41.
11. Stolarek IH, Brodie AF, Brodie MJ. Management of seizures in the elderly: a survey of UK geriatricians, J R Soc Med 1995;88:686-9.
12. King-Stephens D. The treatment of epilepsy in the elderly. CNS Drugs 1999;12:21-33.
13. Bernus I, Dickinson RG, Hooper WD, et al. Anticonvulsant therapy in aged patients: clinical pharmacokinetic considerations. Drugs Aging 1997;10:278-89.
14. Parker BM, Cusack BJ, Vestal RE. Pharmacokinetic optimisation of drug therapy in elderly patients. Drugs Aging 1995;7:10-8.
15. Leppik IE. Epilepsy in the elderly. Curr Neurol Neurosci Rep 2001;1:396-402.
16. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects ofcarbamazepine and carbamazepine-10,11-epoxide: an update. Clin Pharmacokinet 1986;11:177-98.
17. Hockings N, Pall A, Moody J, et al. The effects of age on carbamazepine pharmacokinetics and adverse effects. Br J Clin Pharmacol 1986;22:725-8.
18. Scheuer ML, McCullough K. Carbamazepine clearance in the elderly. Neurology 1995;45(suppl 4):360.
19. Graves NM, Brundage RC, Wen Y, et al. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy 1998;18:273-81.
20. Kudriakova TB, Sirota LA, Rozova GI, et al. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol 1992;33:611-5.
21. Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 2001;18:837-51.
22. Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 1998;23:247-55.
23. Koyama H, Sugioka N, Uno A, et al. Age-related alteration of carbamazepine-serum protein binding in man. J Pharm Pharmacol 1999;51:1009-14.
24. Bachmann KA, Belloto RJ Jr. Differential kinetics of phenytoin in elderly patients. Drugs Aging 1999;15:235-50.
25. Perucca E, Grimaldi R, Gatti G, et al. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 1984;17:665-9.
26. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet 1996;31:198-214.
27. Salem SA, Rajjayabun P, Shepherd AM, et al. Reduced induction of drug metabolism in the elderly. Age Ageing 1978;7:68-73.
28. Twum-Barima Y, Finnigan T, Habash AI, et al. Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol 1984;17:595-7.
29. Vestal RE, Wood AJ, Branch RA, et al. Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther 1979;26:8-15.
30. Vestal RE, Norris AH, Tobin JD, et al. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin Pharmacol Ther 1975;18:425-32.
31. Crowley JJ, Cusack BJ, Jue SG, et al. Aging and drug interactions, II: effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. J Pharmacol Exp Ther 1988;245:513-23.
32. Greenblatt DJ, Divoll MK, Abemethy DR, et al. Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. Pharmacology 1989;38:327-34.
33. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001;42:1255-60.